SOLID TUMOURS:@0.084848:0.038601:0.266058:0.038601:0.266058:0.019343:0.084848:0.019343:0.011712:0.020438:0.010866:0.005315:0.017498:0.006515:0.010019:0.015405:0.021613:0.020438:0.015405:0.014276:0.011712
44:@0.023705:0.038809:0.044778:0.038809:0.044778:0.019212:0.023705:0.019212:0.010536:0.010536
HANDBOOK OF ONCOLOGY:@0.084848:0.970015:0.320957:0.970015:0.320957:0.956010:0.084848:0.956010:0.011682:0.012657:0.012657:0.012726:0.009818:0.014864:0.014864:0.010109:0.004738:0.014864:0.008296:0.004738:0.014864:0.012657:0.013906:0.014864:0.007902:0.014864:0.014915:0.010126
of recurrence, but results of randomised :@0.084242:0.096166:0.480490:0.096166:0.480490:0.080410:0.084242:0.080410:0.012604:0.006042:0.009429:0.005713:0.012508:0.012450:0.011699:0.005792:0.005707:0.012508:0.011738:0.012450:0.012508:0.005330:0.009429:0.013123:0.011699:0.006523:0.009429:0.005713:0.012508:0.007466:0.011699:0.003848:0.006523:0.007466:0.009429:0.012604:0.006042:0.009429:0.005792:0.013143:0.011738:0.013181:0.012604:0.018049:0.003848:0.007466:0.012508:0.013181:0.005330
trials are awaited.:@0.084242:0.112689:0.250558:0.112689:0.250558:0.096933:0.084242:0.096933:0.006523:0.005792:0.003848:0.013143:0.003848:0.007466:0.005330:0.013143:0.005719:0.012508:0.005330:0.013143:0.015990:0.013143:0.003848:0.006523:0.012508:0.013181:0.005330
SUMMARY:@0.084242:0.146399:0.199483:0.146399:0.199483:0.126803:0.084242:0.126803:0.012230:0.015052:0.021167:0.021167:0.017404:0.013641:0.014581
Colorectal cancer is a common  disease :@0.084242:0.165222:0.480463:0.165222:0.480463:0.149466:0.084242:0.149466:0.015644:0.012604:0.003848:0.012604:0.005707:0.012508:0.012450:0.006523:0.013143:0.003848:0.008775:0.012450:0.013143:0.011738:0.012450:0.012508:0.005792:0.008775:0.003848:0.007466:0.008775:0.013143:0.008775:0.012450:0.012604:0.018049:0.018049:0.012604:0.011738:0.005330:0.003433:0.013181:0.003848:0.007466:0.012508:0.013143:0.007466:0.012508:0.005330
and screening is effective in reducing :@0.084242:0.181745:0.480501:0.181745:0.480501:0.165989:0.084242:0.165989:0.013143:0.011738:0.013181:0.013566:0.007466:0.012450:0.005713:0.012508:0.012508:0.011738:0.003848:0.011738:0.012941:0.013566:0.003848:0.007466:0.013566:0.012508:0.006096:0.006042:0.012508:0.012450:0.006523:0.003848:0.010660:0.012508:0.013566:0.003848:0.011738:0.013566:0.005711:0.012508:0.013181:0.011699:0.012450:0.003848:0.011738:0.012950:0.005330
mortality. Treatment of localised disease :@0.084242:0.198268:0.480478:0.198268:0.480478:0.182512:0.084242:0.182512:0.018049:0.012604:0.005792:0.006523:0.013143:0.003848:0.003848:0.006523:0.010314:0.005330:0.009737:0.007620:0.005711:0.012508:0.013143:0.006523:0.018049:0.012508:0.011738:0.006523:0.009737:0.012604:0.006042:0.009737:0.003848:0.012604:0.012450:0.013143:0.003848:0.003848:0.007466:0.012508:0.013181:0.009737:0.013181:0.003848:0.007466:0.012508:0.013143:0.007466:0.012508:0.005330
in  the  colon  is  surgery  followed  by ad-:@0.084242:0.214791:0.475148:0.214791:0.475148:0.199035:0.084242:0.199035:0.003848:0.011738:0.005330:0.005626:0.006523:0.011738:0.012508:0.005330:0.005619:0.012450:0.012604:0.003848:0.012604:0.011738:0.005330:0.005617:0.003848:0.007466:0.005330:0.005625:0.007466:0.011699:0.005809:0.012950:0.012508:0.005792:0.010314:0.005330:0.005619:0.006042:0.012604:0.003848:0.003848:0.012604:0.015990:0.012508:0.013181:0.005330:0.005625:0.013123:0.010314:0.010968:0.013143:0.013181:0.006388
juvant chemotherapy for patients with :@0.084242:0.231314:0.480472:0.231314:0.480472:0.215559:0.084242:0.215559:0.003906:0.011699:0.010660:0.013143:0.011738:0.006523:0.013835:0.012450:0.011738:0.012508:0.018049:0.012594:0.006523:0.011738:0.012508:0.005792:0.013143:0.013123:0.010314:0.013835:0.006042:0.012604:0.005792:0.013835:0.013123:0.013143:0.006523:0.003848:0.012508:0.011738:0.006523:0.007466:0.013835:0.015990:0.003848:0.006523:0.011738:0.005330
stage  III  disease.  Neoadjuvant  chemora-:@0.084242:0.247838:0.475152:0.247838:0.475152:0.232082:0.084242:0.232082:0.007466:0.006523:0.013143:0.012950:0.012508:0.005330:0.003123:0.004349:0.004349:0.004349:0.005330:0.003125:0.013181:0.003848:0.007466:0.012508:0.013143:0.007478:0.012508:0.005330:0.005330:0.003121:0.014239:0.012508:0.012604:0.013143:0.013181:0.003906:0.011699:0.010660:0.013143:0.011738:0.006523:0.005330:0.003121:0.012450:0.011738:0.012508:0.018049:0.012604:0.005792:0.013129:0.006388
diation is indicated for locally advanced :@0.084242:0.264361:0.480467:0.264361:0.480467:0.248605:0.084242:0.248605:0.013181:0.003848:0.013143:0.006523:0.003848:0.012604:0.011738:0.007957:0.003848:0.007466:0.007966:0.003848:0.011738:0.013181:0.003848:0.012450:0.013143:0.006523:0.012508:0.013181:0.007953:0.006042:0.012604:0.005792:0.007947:0.003848:0.012604:0.012450:0.013143:0.003848:0.003848:0.010314:0.007955:0.013143:0.013181:0.010660:0.013143:0.011738:0.012450:0.012508:0.013181:0.005330
rectal  cancer.  The  combination  of  surgi-:@0.084242:0.280884:0.475150:0.280884:0.475150:0.265128:0.084242:0.265128:0.005713:0.012508:0.012450:0.006523:0.013143:0.003848:0.005330:0.003837:0.012450:0.013143:0.011738:0.012450:0.012508:0.004374:0.005330:0.005330:0.003835:0.008197:0.011738:0.012508:0.005330:0.003827:0.012450:0.012604:0.018049:0.013123:0.003848:0.011738:0.013143:0.006523:0.003848:0.012604:0.011738:0.005330:0.003831:0.012604:0.006042:0.005330:0.003833:0.007466:0.011699:0.005807:0.012950:0.003848:0.006388
cal techniques and systemic treatment al-:@0.084242:0.297407:0.475160:0.297407:0.475160:0.281651:0.084242:0.281651:0.012450:0.013143:0.003848:0.004926:0.006523:0.012508:0.012450:0.011738:0.011738:0.003848:0.013123:0.011699:0.012508:0.007466:0.004915:0.013143:0.011738:0.013181:0.004915:0.007466:0.010314:0.007466:0.006523:0.012508:0.018049:0.003848:0.012450:0.004926:0.006523:0.005709:0.012508:0.013143:0.006523:0.018049:0.012508:0.011738:0.006523:0.004905:0.013143:0.003848:0.006388
lows for resection of metastases, offering :@0.084242:0.313931:0.480511:0.313931:0.480511:0.298175:0.084242:0.298175:0.003848:0.012604:0.015990:0.007466:0.008178:0.006042:0.012604:0.005792:0.008178:0.005713:0.012508:0.007466:0.012508:0.012450:0.006523:0.003848:0.012604:0.011738:0.008178:0.012604:0.006042:0.008178:0.018049:0.012508:0.006523:0.013143:0.007466:0.006523:0.013143:0.007466:0.012508:0.007466:0.005330:0.008178:0.012604:0.006092:0.006042:0.012508:0.005792:0.003848:0.011738:0.012950:0.005330
potentially curative treatment. A number :@0.084242:0.330454:0.480519:0.330454:0.480519:0.314698:0.084242:0.314698:0.013123:0.012604:0.006523:0.012508:0.011738:0.006523:0.003848:0.013143:0.003848:0.003848:0.010314:0.007658:0.012450:0.011699:0.005792:0.013143:0.006523:0.003848:0.010660:0.012508:0.007658:0.006523:0.005709:0.012508:0.013143:0.006523:0.018049:0.012508:0.011738:0.006523:0.005330:0.007641:0.014239:0.007641:0.011738:0.011699:0.018049:0.013123:0.012508:0.005792:0.005330
of effective treatment regimens are now :@0.084242:0.346977:0.480511:0.346977:0.480511:0.331221:0.084242:0.331221:0.012604:0.006042:0.007889:0.012508:0.006098:0.006042:0.012508:0.012450:0.006523:0.003848:0.010660:0.012508:0.007889:0.006523:0.005709:0.012508:0.013143:0.006523:0.018049:0.012508:0.011738:0.006523:0.007889:0.005713:0.012508:0.012950:0.003848:0.018049:0.012508:0.011738:0.007466:0.007889:0.013143:0.005715:0.012508:0.007889:0.011738:0.012604:0.015990:0.005330
available  for  patients with unresectable :@0.084242:0.363500:0.480494:0.363500:0.480494:0.347744:0.084242:0.347744:0.013143:0.010660:0.013143:0.003848:0.003848:0.013143:0.013123:0.003848:0.012508:0.005330:0.005440:0.006042:0.012604:0.005792:0.005330:0.005411:0.013123:0.013143:0.006523:0.003848:0.012508:0.011738:0.006523:0.007466:0.010757:0.015990:0.003848:0.006523:0.011738:0.010757:0.011699:0.011738:0.005709:0.012508:0.007466:0.012508:0.012450:0.006523:0.013143:0.013123:0.003848:0.012508:0.005330
metastases, resulting in improved survival.:@0.084242:0.380024:0.469702:0.380024:0.469702:0.364268:0.084242:0.364268:0.018049:0.012508:0.006523:0.013143:0.007466:0.006523:0.013143:0.007466:0.012508:0.007466:0.005330:0.005330:0.005713:0.012508:0.007466:0.011699:0.003848:0.006523:0.003848:0.011738:0.012950:0.005330:0.003848:0.011738:0.005330:0.003848:0.018049:0.013123:0.005713:0.012604:0.010660:0.012508:0.013181:0.005330:0.007466:0.011699:0.005792:0.010660:0.003848:0.010660:0.013143:0.003848:0.005330
REFERENCES:@0.084242:0.410146:0.195079:0.410146:0.195079:0.394113:0.084242:0.394113:0.011161:0.010006:0.009236:0.010006:0.011161:0.010006:0.014239:0.015009:0.010006:0.010006
1. :@0.084242:0.427304:0.103194:0.427304:0.103194:0.413299:0.084242:0.413299:0.009479:0.004734:0.004738
 National  Health  Laboratory  Service (NHLS). :@0.120589:0.427304:0.479906:0.427304:0.479906:0.413299:0.120589:0.413299:0.000000:0.012144:0.011169:0.005285:0.002908:0.010690:0.009921:0.011169:0.002908:0.004738:0.005396:0.011169:0.010605:0.011169:0.002908:0.005285:0.009921:0.004738:0.005396:0.007389:0.011169:0.011152:0.010690:0.004635:0.011169:0.005285:0.010690:0.004635:0.008655:0.004738:0.005396:0.008005:0.010605:0.004635:0.008963:0.002908:0.010553:0.010605:0.010143:0.005798:0.012144:0.011169:0.007389:0.008005:0.005798:0.004734:0.004738
National Cancer Registry South Africa:@0.120589:0.441780:0.427424:0.441780:0.427424:0.427775:0.120589:0.427775:0.012144:0.011169:0.005285:0.002908:0.010690:0.009921:0.011169:0.002908:0.007680:0.013393:0.011169:0.009921:0.010553:0.010605:0.004635:0.007680:0.009869:0.010605:0.010998:0.002908:0.006123:0.005285:0.004635:0.008655:0.007680:0.008005:0.010690:0.009886:0.005285:0.009921:0.007680:0.012144:0.004858:0.004635:0.002908:0.010553:0.011682
 2013. :@0.426911:0.441780:0.479914:0.441780:0.479914:0.427775:0.426911:0.427775:0.007680:0.008963:0.008963:0.008963:0.008963:0.004734:0.004738
Available at http://www.nioh.ac.za/assets/:@0.120589:0.456256:0.475137:0.456256:0.475137:0.442250:0.120589:0.442250:0.010887:0.008963:0.011169:0.002908:0.002908:0.011169:0.011152:0.002908:0.010605:0.014453:0.011169:0.005285:0.014453:0.009921:0.005285:0.005285:0.011152:0.004225:0.006961:0.006961:0.013701:0.013701:0.013701:0.004225:0.009921:0.002908:0.010690:0.009921:0.004225:0.011169:0.010553:0.004225:0.006756:0.011169:0.006961:0.011169:0.006123:0.006123:0.010605:0.005285:0.006123:0.007475
files/NCR2013.pdf. Accessed 11 January 2018.:@0.120589:0.470731:0.475130:0.470731:0.475130:0.456726:0.120589:0.456726:0.003908:0.003908:0.002908:0.010605:0.006123:0.006961:0.012144:0.013393:0.009869:0.008963:0.008963:0.008963:0.008963:0.004225:0.011152:0.011203:0.004858:0.004225:0.003404:0.012144:0.010553:0.010553:0.010605:0.006123:0.006123:0.010605:0.011203:0.003405:0.008963:0.008963:0.003404:0.007731:0.011169:0.009921:0.009886:0.011169:0.004635:0.008655:0.003404:0.008963:0.008963:0.008963:0.008963:0.004738
2. :@0.084242:0.485207:0.103194:0.485207:0.103194:0.471202:0.084242:0.471202:0.009476:0.004738:0.004738
 Zauber  AG,:@0.120589:0.485207:0.226896:0.485207:0.226896:0.471202:0.120589:0.471202:0.000000:0.008210:0.011682:0.010399:0.011665:0.011118:0.005148:0.004738:0.011036:0.012657:0.014915:0.004738
  et  al.:@0.226896:0.485207:0.295204:0.485207:0.295204:0.471202:0.226896:0.471202:0.004738:0.011039:0.011118:0.005798:0.004738:0.011036:0.011682:0.003421:0.004738
  Colonoscopic  pol-:@0.295204:0.485207:0.475151:0.485207:0.475151:0.471202:0.295204:0.471202:0.004738:0.011039:0.013906:0.011203:0.003421:0.011203:0.010434:0.011203:0.006636:0.011067:0.011203:0.011665:0.003421:0.011067:0.004738:0.011034:0.011665:0.011203:0.003421:0.005679
ypectomy and long-term prevention of :@0.120589:0.499683:0.479902:0.499683:0.479902:0.485677:0.120589:0.485677:0.009168:0.011665:0.011118:0.011067:0.005798:0.011203:0.016044:0.009168:0.012093:0.011682:0.010434:0.011716:0.012093:0.003421:0.011203:0.010434:0.011511:0.005679:0.005798:0.011118:0.005612:0.016044:0.012093:0.011665:0.005080:0.011118:0.009476:0.011118:0.010434:0.005798:0.003421:0.011203:0.010434:0.012093:0.011203:0.005371:0.004738
colorectal-cancer  deaths. :@0.120589:0.514158:0.347188:0.514158:0.347188:0.500153:0.120589:0.500153:0.011067:0.011203:0.003421:0.011203:0.005073:0.011118:0.011067:0.005798:0.011682:0.003421:0.005679:0.011067:0.011682:0.010434:0.011067:0.011118:0.005148:0.004738:0.003753:0.011716:0.011118:0.011682:0.005798:0.010434:0.006636:0.004738:0.004738
N  Engl J Med.:@0.350951:0.514158:0.475171:0.514158:0.475171:0.500153:0.350951:0.500153:0.012657:0.004738:0.003754:0.009168:0.010434:0.011511:0.003421:0.008501:0.008244:0.008501:0.015719:0.011118:0.011716:0.004738
 :@0.475171:0.514158:0.479909:0.514158:0.479909:0.500153:0.475171:0.500153:0.004738
2012;366(12):687-96.:@0.120589:0.528634:0.285766:0.528634:0.285766:0.514629:0.120589:0.514629:0.009476:0.009476:0.009476:0.009476:0.004738:0.009476:0.009476:0.009476:0.006312:0.009476:0.009476:0.006312:0.004738:0.009476:0.009476:0.009476:0.005679:0.009476:0.009476:0.004738
3. :@0.084242:0.543109:0.103194:0.543109:0.103194:0.529104:0.084242:0.529104:0.009476:0.004738:0.004738
 Brenner H,:@0.120589:0.543109:0.205150:0.543109:0.205150:0.529104:0.120589:0.529104:0.000000:0.009818:0.005082:0.011118:0.010434:0.010434:0.011118:0.005148:0.004989:0.011682:0.004738
 et al.:@0.205150:0.543109:0.251908:0.543109:0.251908:0.529104:0.205150:0.529104:0.005001:0.011118:0.005798:0.005000:0.011682:0.003421:0.004738
 Effect of screening sigmoi-:@0.251908:0.543109:0.475147:0.543109:0.475147:0.529104:0.251908:0.529104:0.005001:0.009168:0.005422:0.005371:0.011118:0.011067:0.005798:0.004996:0.011203:0.005371:0.004998:0.006636:0.011067:0.005080:0.011118:0.011118:0.010434:0.003421:0.010434:0.011511:0.004993:0.006636:0.003421:0.011511:0.016044:0.011203:0.003421:0.005679
doscopy and screening colonoscopy on :@0.120589:0.557585:0.479888:0.557585:0.479888:0.543580:0.120589:0.543580:0.011716:0.011203:0.006636:0.011067:0.011203:0.011665:0.009168:0.009339:0.011682:0.010434:0.011716:0.009339:0.006636:0.011067:0.005078:0.011118:0.011118:0.010434:0.003421:0.010434:0.011511:0.009339:0.011067:0.011203:0.003421:0.011203:0.010434:0.011193:0.006636:0.011067:0.011203:0.011665:0.009168:0.009339:0.011203:0.010434:0.004738
colorectal cancer  incidence  and mortal-:@0.120589:0.572061:0.475168:0.572061:0.475168:0.558055:0.120589:0.558055:0.011067:0.011203:0.003421:0.011203:0.005073:0.011118:0.011067:0.005798:0.011682:0.003421:0.008107:0.011067:0.011682:0.010434:0.011067:0.011118:0.005148:0.004738:0.003356:0.003421:0.010434:0.011067:0.003421:0.011716:0.011118:0.010434:0.011067:0.011118:0.004738:0.003361:0.011682:0.010434:0.011716:0.008107:0.016044:0.011203:0.005148:0.005798:0.011682:0.003421:0.005679
ity: systematic review and meta-analysis of :@0.120589:0.586536:0.479894:0.586536:0.479894:0.572531:0.120589:0.572531:0.003421:0.005798:0.009168:0.004738:0.005166:0.006636:0.009168:0.006636:0.005798:0.011118:0.016044:0.011682:0.005798:0.003421:0.011067:0.005166:0.005078:0.011118:0.009476:0.003421:0.011118:0.014214:0.005166:0.011682:0.010434:0.011716:0.005166:0.016044:0.011118:0.005798:0.011682:0.005679:0.011682:0.010434:0.011682:0.003421:0.009168:0.006636:0.003421:0.006636:0.005177:0.011203:0.005371:0.004738
randomised controlled trials and observa-:@0.120589:0.601012:0.475168:0.601012:0.475168:0.587007:0.120589:0.587007:0.005148:0.011682:0.010434:0.011716:0.011203:0.016044:0.003421:0.006636:0.011118:0.011716:0.007107:0.011067:0.011203:0.010434:0.005798:0.005077:0.011203:0.003421:0.003421:0.011118:0.011716:0.007115:0.005798:0.005148:0.003421:0.011682:0.003421:0.006636:0.007115:0.011682:0.010434:0.011716:0.007115:0.011203:0.011665:0.006636:0.011118:0.005148:0.009476:0.011682:0.005679
tional studies. :@0.120589:0.615488:0.236488:0.615488:0.236488:0.601482:0.120589:0.601482:0.005798:0.003421:0.011203:0.010434:0.011682:0.003421:0.004738:0.006636:0.005798:0.010399:0.011716:0.003421:0.011118:0.006636:0.004738:0.004738
BMJ:@0.236488:0.615488:0.270269:0.615488:0.270269:0.601482:0.236488:0.601482:0.009818:0.015719:0.008244
. 2014;348:g2467.:@0.270269:0.615488:0.409704:0.615488:0.409704:0.601482:0.270269:0.601482:0.004738:0.004738:0.009476:0.009476:0.009476:0.009476:0.004738:0.009476:0.009476:0.009476:0.004738:0.011511:0.009476:0.009476:0.009476:0.009476:0.004738
4. :@0.084242:0.629963:0.103194:0.629963:0.103194:0.615958:0.084242:0.615958:0.009476:0.004738:0.004738
 Inadomi JM. Screening for colorectal neo-:@0.120589:0.629963:0.475145:0.629963:0.475145:0.615958:0.120589:0.615958:0.000000:0.003866:0.010434:0.011682:0.011716:0.011203:0.016044:0.003421:0.005918:0.008244:0.015719:0.004738:0.005918:0.008518:0.011067:0.005078:0.011118:0.011118:0.010434:0.003421:0.010434:0.011511:0.005918:0.005371:0.011203:0.005148:0.005918:0.011067:0.011203:0.003421:0.011203:0.005073:0.011118:0.011067:0.005798:0.011682:0.003421:0.005918:0.010434:0.011118:0.011195:0.005679
plasia. :@0.120589:0.644439:0.178573:0.644439:0.178573:0.630434:0.120589:0.630434:0.011665:0.003421:0.011682:0.006636:0.003421:0.011682:0.004738:0.004738
N Engl J Med.:@0.178590:0.644439:0.291530:0.644439:0.291530:0.630434:0.178590:0.630434:0.012657:0.004738:0.009168:0.010434:0.011511:0.003421:0.004738:0.008244:0.004738:0.015719:0.011118:0.011716:0.004738
 2017;376:149-56.:@0.291513:0.644439:0.429853:0.644439:0.429853:0.630434:0.291513:0.630434:0.004738:0.009476:0.009476:0.009476:0.009476:0.004738:0.009476:0.009476:0.009476:0.004738:0.009476:0.009476:0.009476:0.005679:0.009476:0.009476:0.004738
5. :@0.084242:0.658915:0.103194:0.658915:0.103194:0.644909:0.084242:0.644909:0.009479:0.004734:0.004738
 Nelson H,:@0.120589:0.658915:0.196946:0.658915:0.196946:0.644909:0.120589:0.644909:0.000000:0.012828:0.011289:0.003592:0.006808:0.011374:0.010605:0.003270:0.011853:0.004738
 et al. :@0.197117:0.658915:0.246002:0.658915:0.246002:0.644909:0.197117:0.644909:0.003267:0.011289:0.005969:0.003267:0.011853:0.003592:0.004909:0.004738
A comparison of laparosco- :@0.244531:0.658915:0.479883:0.658915:0.479883:0.644909:0.244531:0.644909:0.012828:0.003267:0.011238:0.011374:0.016215:0.011836:0.011853:0.005319:0.003592:0.006808:0.011374:0.010605:0.003267:0.011374:0.005542:0.003267:0.003592:0.011853:0.011836:0.011853:0.005249:0.011374:0.006808:0.011238:0.011374:0.005677:0.004738
pically  assisted  and open  colectomy for :@0.120589:0.673390:0.479888:0.673390:0.479888:0.659385:0.120589:0.659385:0.011836:0.003592:0.011238:0.011853:0.003592:0.003592:0.009339:0.004738:0.003532:0.011853:0.006808:0.006808:0.003592:0.006808:0.005969:0.011289:0.011888:0.004738:0.003532:0.011853:0.010605:0.011888:0.008279:0.011374:0.011836:0.011289:0.010605:0.004738:0.003532:0.011238:0.011374:0.003592:0.011289:0.011238:0.005969:0.011374:0.016215:0.009339:0.008279:0.005542:0.011374:0.005145:0.004738
colon  cancer. :@0.559983:0.094811:0.691090:0.094811:0.691090:0.080806:0.559983:0.080806:0.011580:0.011716:0.003934:0.011716:0.010947:0.004738:0.004148:0.011580:0.012195:0.010947:0.011580:0.011631:0.004406:0.005251:0.004738
N  Engl  J  Med.:@0.695227:0.094811:0.825227:0.094811:0.825227:0.080806:0.695227:0.080806:0.013170:0.004738:0.004146:0.009681:0.010947:0.012024:0.003934:0.004738:0.004148:0.008757:0.004738:0.004148:0.016232:0.011631:0.012230:0.004738
  2004;350: :@0.825740:0.094811:0.919294:0.094811:0.919294:0.080806:0.825740:0.080806:0.004738:0.004148:0.009989:0.009989:0.009989:0.009989:0.005251:0.009989:0.009989:0.009989:0.004757:0.004738
2050-59.:@0.560000:0.109275:0.630864:0.109275:0.630864:0.095270:0.560000:0.095270:0.009989:0.009989:0.009989:0.009989:0.006192:0.009989:0.009989:0.004738
6. :@0.523653:0.123739:0.542605:0.123739:0.542605:0.109734:0.523653:0.109734:0.009476:0.004738:0.004738
  Bipat S,:@0.560000:0.123739:0.621600:0.123739:0.621600:0.109734:0.560000:0.109734:0.004738:-0.004738:0.009818:0.003421:0.011665:0.011682:0.005798:0.005959:0.008518:0.004738
 et al.:@0.621600:0.123739:0.670262:0.123739:0.670262:0.109734:0.621600:0.109734:0.005952:0.011118:0.005798:0.005952:0.011682:0.003421:0.004738
 Rectal cancer: local staging :@0.670262:0.123739:0.919306:0.123739:0.919306:0.109734:0.670262:0.109734:0.005952:0.010382:0.011118:0.011067:0.005798:0.011682:0.003421:0.005952:0.011067:0.011682:0.010434:0.011067:0.011118:0.005148:0.004738:0.005940:0.003421:0.011203:0.011067:0.011682:0.003421:0.005952:0.006636:0.005798:0.011682:0.011511:0.003421:0.010434:0.011511:0.004738
and assessment of  lymph node involve-:@0.560000:0.138203:0.914565:0.138203:0.914565:0.124198:0.560000:0.124198:0.011682:0.010434:0.011716:0.010399:0.011682:0.006636:0.006636:0.011118:0.006636:0.006636:0.016044:0.011118:0.010434:0.005798:0.010399:0.011203:0.005371:0.004738:0.005653:0.003421:0.009168:0.016044:0.011665:0.010434:0.010399:0.010434:0.011203:0.011716:0.011118:0.010399:0.003421:0.010434:0.009476:0.011203:0.003421:0.009476:0.011118:0.005679
ment  with endoluminal US,  CT, and MR :@0.560000:0.152667:0.919322:0.152667:0.919322:0.138662:0.560000:0.138662:0.016044:0.011118:0.010434:0.005798:0.004738:0.006164:0.014214:0.003421:0.005798:0.010434:0.010913:0.011118:0.010434:0.011716:0.011203:0.003421:0.010399:0.016044:0.003421:0.010434:0.011682:0.003421:0.010913:0.011203:0.008518:0.004738:0.004738:0.006166:0.013906:0.005537:0.004738:0.010913:0.011682:0.010434:0.011716:0.010913:0.015719:0.010382:0.004738
Imaging – a meta-analysis. :@0.560000:0.167131:0.816018:0.167131:0.816018:0.153125:0.560000:0.153125:0.003866:0.016044:0.011682:0.011511:0.003421:0.010434:0.011511:0.014812:0.008552:0.014812:0.011682:0.014812:0.016044:0.011118:0.005798:0.011682:0.005679:0.011682:0.010434:0.011682:0.003421:0.009168:0.006636:0.003421:0.006636:0.004738:0.004738
Radiology.:@0.826110:0.167131:0.914556:0.167131:0.914556:0.153125:0.826110:0.153125:0.010382:0.011682:0.011716:0.003421:0.011203:0.003421:0.011203:0.011511:0.009168:0.004738
 :@0.914556:0.167131:0.919294:0.167131:0.919294:0.153125:0.914556:0.153125:0.004738
2004;232:773-83.:@0.560000:0.181595:0.693602:0.181595:0.693602:0.167589:0.560000:0.167589:0.009476:0.009476:0.009476:0.009476:0.004738:0.009476:0.009476:0.009476:0.004738:0.009476:0.009476:0.009476:0.005679:0.009476:0.009476:0.004738
7. :@0.523653:0.196058:0.542605:0.196058:0.542605:0.182053:0.523653:0.182053:0.009479:0.004734:0.004738
  MacFarlane  JK,:@0.559998:0.196058:0.689708:0.196058:0.689708:0.182053:0.559998:0.182053:0.004738:-0.004738:0.015548:0.011511:0.010895:0.008125:0.011511:0.004977:0.003250:0.011511:0.010263:0.010947:0.004738:0.003684:0.008073:0.009938:0.004738
  et  al. :@0.689537:0.196058:0.747021:0.196058:0.747021:0.182053:0.689537:0.182053:0.004738:0.003684:0.010947:0.005627:0.004738:0.003684:0.011511:0.003250:0.004567:0.004738
Mesorectal  excision :@0.750697:0.196058:0.919296:0.196058:0.919296:0.182053:0.750697:0.182053:0.015548:0.010947:0.006465:0.011032:0.004907:0.010947:0.010895:0.005627:0.011511:0.003250:0.004738:0.003684:0.010947:0.008039:0.010895:0.003250:0.006465:0.003250:0.011032:0.010430:0.004738
for rectal cancer. :@0.560000:0.210522:0.705016:0.210522:0.705016:0.196517:0.560000:0.196517:0.005200:0.011032:0.004977:0.004567:0.004906:0.010947:0.010895:0.005627:0.011511:0.003250:0.004567:0.010895:0.011511:0.010263:0.010895:0.010947:0.003720:0.004567:0.004738
Lancet.:@0.704845:0.210522:0.766558:0.210522:0.766558:0.196517:0.704845:0.196517:0.007731:0.011511:0.010263:0.010895:0.010947:0.005627:0.004738
 1993;341:457-460.:@0.766387:0.210522:0.911295:0.210522:0.911295:0.196517:0.766387:0.196517:0.004567:0.009305:0.009305:0.009305:0.009305:0.004567:0.009305:0.009305:0.009305:0.004567:0.009305:0.009305:0.009305:0.005508:0.009305:0.009305:0.009305:0.004738
8. :@0.523653:0.224986:0.542605:0.224986:0.542605:0.210981:0.523653:0.210981:0.009476:0.004738:0.004738
  Andre  T,:@0.560000:0.224986:0.631474:0.224986:0.631474:0.210981:0.560000:0.210981:0.004738:-0.004738:0.012657:0.010434:0.011716:0.005071:0.011118:0.004738:0.005465:0.005537:0.004738
 et  al.:@0.631474:0.224986:0.688642:0.224986:0.688642:0.210981:0.631474:0.210981:0.010211:0.011118:0.005798:0.004738:0.005461:0.011682:0.003421:0.004738
 Improved  overall survival :@0.688642:0.224986:0.919305:0.224986:0.919305:0.210981:0.688642:0.210981:0.010211:0.003866:0.016044:0.011665:0.005082:0.011203:0.009476:0.011118:0.011716:0.004738:0.005465:0.011203:0.009476:0.011118:0.005148:0.011682:0.003421:0.003421:0.010211:0.006636:0.010399:0.005148:0.009476:0.003421:0.009476:0.011682:0.003421:0.004738
with  oxaliplatin,  fluorouracil,  and  leucov-:@0.560000:0.239450:0.914563:0.239450:0.914563:0.225445:0.560000:0.225445:0.014214:0.003421:0.005798:0.010434:0.004738:0.005099:0.011203:0.008210:0.011682:0.003421:0.003421:0.011665:0.003421:0.011682:0.005798:0.003421:0.010434:0.004738:0.004738:0.005111:0.004148:0.004148:0.010399:0.011203:0.005070:0.011203:0.010399:0.005148:0.011682:0.011067:0.003421:0.003421:0.004738:0.004738:0.005097:0.011682:0.010434:0.011716:0.004738:0.005099:0.003421:0.011118:0.010399:0.011067:0.011203:0.009476:0.005679
orin as adjuvant treatment in stage II or III :@0.560000:0.253914:0.919306:0.253914:0.919306:0.239909:0.560000:0.239909:0.011203:0.005148:0.003421:0.010434:0.006524:0.011682:0.006636:0.006534:0.011682:0.011716:0.003472:0.010399:0.009476:0.011682:0.010434:0.005798:0.006534:0.005798:0.005077:0.011118:0.011682:0.005798:0.016044:0.011118:0.010434:0.005798:0.006520:0.003421:0.010434:0.006534:0.006636:0.005798:0.011682:0.011511:0.011118:0.006534:0.003866:0.003866:0.006534:0.011203:0.005148:0.006522:0.003866:0.003866:0.003866:0.004738
colon cancer in the MOSAIC trial:@0.560000:0.268378:0.827647:0.268378:0.827647:0.254373:0.560000:0.254373:0.011067:0.011203:0.003421:0.011203:0.010434:0.003917:0.011067:0.011682:0.010434:0.011067:0.011118:0.005148:0.003915:0.003421:0.010434:0.003925:0.005798:0.010434:0.011118:0.003919:0.015719:0.014864:0.008518:0.012657:0.003866:0.013906:0.003924:0.005798:0.005148:0.003421:0.011682:0.003421
. J Clin On-:@0.827647:0.268378:0.914565:0.268378:0.914565:0.254373:0.827647:0.254373:0.004738:0.003922:0.008244:0.003922:0.013906:0.003421:0.003421:0.010434:0.003934:0.014864:0.010434:0.005679
col.:@0.560000:0.282842:0.590429:0.282842:0.590429:0.268836:0.560000:0.268836:0.011067:0.011203:0.003421:0.004738
 2009; 27:3109-16.:@0.590429:0.282842:0.733507:0.282842:0.733507:0.268836:0.590429:0.268836:0.004738:0.009476:0.009476:0.009476:0.009476:0.004738:0.004738:0.009476:0.009476:0.004738:0.009476:0.009476:0.009476:0.009476:0.005679:0.009476:0.009476:0.004738
9. :@0.523653:0.297306:0.542605:0.297306:0.542605:0.283300:0.523653:0.283300:0.009476:0.004738:0.004738
  Prospective pooled analysis of six phase :@0.560000:0.297306:0.919306:0.297306:0.919306:0.283300:0.560000:0.283300:0.004738:-0.004738:0.010126:0.005075:0.011203:0.006636:0.011665:0.011118:0.011067:0.005798:0.003421:0.009476:0.011118:0.009613:0.011665:0.011203:0.011203:0.003421:0.011118:0.011716:0.009613:0.011682:0.010434:0.011682:0.003421:0.009168:0.006636:0.003421:0.006654:0.009613:0.011203:0.005371:0.009613:0.006636:0.003421:0.008210:0.009613:0.011665:0.010434:0.011682:0.006636:0.011118:0.004738
III trials  investigating duration of adjuvant :@0.560000:0.311770:0.919288:0.311770:0.919288:0.297764:0.560000:0.297764:0.003866:0.003866:0.003866:0.008227:0.005798:0.005148:0.003421:0.011682:0.003421:0.006636:0.004738:0.003500:0.003421:0.010434:0.009476:0.011118:0.006636:0.005798:0.003421:0.011511:0.011682:0.005798:0.003421:0.010434:0.011511:0.008227:0.011716:0.010399:0.005148:0.011682:0.005798:0.003421:0.011203:0.010434:0.008227:0.011203:0.005371:0.008227:0.011682:0.011716:0.003472:0.010399:0.009476:0.011682:0.010434:0.005798:0.004738
oxaliplatin based therapy for patients with :@0.560000:0.326233:0.919293:0.326233:0.919293:0.312228:0.560000:0.312228:0.011203:0.008210:0.011682:0.003421:0.003421:0.011665:0.003421:0.011682:0.005798:0.003421:0.010434:0.006055:0.011665:0.011682:0.006636:0.011118:0.011716:0.006045:0.005798:0.010434:0.011118:0.005148:0.011682:0.011665:0.009168:0.006041:0.005371:0.011203:0.005148:0.006036:0.011665:0.011682:0.005798:0.003421:0.011118:0.010434:0.005798:0.006636:0.006045:0.014214:0.003421:0.005798:0.010434:0.004738
stage  III colon  cancer:  the  IDEA (Interna-:@0.560000:0.340697:0.914567:0.340697:0.914567:0.326692:0.560000:0.326692:0.006636:0.005798:0.011682:0.011511:0.011118:0.004738:0.003104:0.003866:0.003866:0.003866:0.007851:0.011067:0.011203:0.003421:0.011203:0.010434:0.004738:0.003099:0.011067:0.011682:0.010434:0.011067:0.011118:0.005148:0.004738:0.004738:0.003098:0.005798:0.010434:0.011118:0.004738:0.003099:0.003866:0.012726:0.009168:0.012657:0.007851:0.006312:0.003866:0.010434:0.005798:0.011118:0.005501:0.010434:0.011682:0.005679
tional Duration  Evaluation of  Adjuvant) :@0.560000:0.355161:0.919303:0.355161:0.919303:0.341156:0.560000:0.341156:0.005798:0.003421:0.011203:0.010434:0.011682:0.003421:0.013153:0.012726:0.010399:0.005148:0.011682:0.005798:0.003421:0.011203:0.010434:0.004738:0.008400:0.009168:0.009476:0.011682:0.003421:0.010399:0.011682:0.005798:0.003421:0.011203:0.010434:0.013153:0.011203:0.005371:0.004738:0.008405:0.012657:0.011716:0.003472:0.010399:0.009476:0.011682:0.010434:0.005798:0.006312:0.004738
chemotherapy collaboration:@0.560000:0.369625:0.802017:0.369625:0.802017:0.355620:0.560000:0.355620:0.011067:0.010434:0.011118:0.016044:0.011203:0.005798:0.010434:0.011118:0.005148:0.011682:0.011665:0.009168:0.005788:0.011067:0.011203:0.003421:0.003421:0.011682:0.011665:0.011203:0.005148:0.011682:0.005798:0.003421:0.011203:0.010434
. J Clin Oncol:@0.802017:0.369625:0.914563:0.369625:0.914563:0.355620:0.802017:0.355620:0.004738:0.005798:0.008244:0.005798:0.013906:0.003421:0.003421:0.010434:0.005798:0.014864:0.010434:0.011067:0.011203:0.003421
 :@0.914563:0.369625:0.919301:0.369625:0.919301:0.355620:0.914563:0.355620:0.004738
35 no. 15. Doi: 10.1200/JCO.2017.35.15.:@0.560000:0.384089:0.880895:0.384089:0.880895:0.370084:0.560000:0.370084:0.009476:0.009476:0.004738:0.010434:0.011203:0.004738:0.004738:0.009476:0.009476:0.004738:0.004738:0.012726:0.011203:0.003421:0.004738:0.004738:0.009476:0.009476:0.004738:0.009476:0.009476:0.009476:0.009476:0.007475:0.008244:0.013906:0.014864:0.004738:0.009476:0.009476:0.009476:0.009476:0.004738:0.009476:0.009476:0.004738:0.009476:0.009476:0.004738
10.   Rolf  S,:@0.523653:0.398553:0.612625:0.398553:0.612625:0.384548:0.523653:0.384548:0.009476:0.009476:0.004738:0.004738:0.007919:0.000000:0.010382:0.011203:0.003421:0.005371:0.004738:0.004254:0.008518:0.004738
 et al.:@0.612625:0.398553:0.667376:0.398553:0.667376:0.384548:0.612625:0.384548:0.008997:0.011118:0.005798:0.008997:0.011682:0.003421:0.004738
 Preoperative versus postop-:@0.667376:0.398553:0.914580:0.398553:0.914580:0.384548:0.667376:0.384548:0.008997:0.010126:0.005075:0.011118:0.011203:0.011665:0.011118:0.005148:0.011682:0.005798:0.003421:0.009476:0.011118:0.008997:0.009476:0.011118:0.005148:0.006636:0.010399:0.006636:0.008997:0.011665:0.011203:0.006636:0.005798:0.011203:0.011665:0.005679
erative chemoradiotherapy for locally ad-:@0.560000:0.413017:0.914562:0.413017:0.914562:0.399011:0.560000:0.399011:0.011118:0.005148:0.011682:0.005798:0.003421:0.009476:0.011118:0.006140:0.011067:0.010434:0.011118:0.016044:0.011203:0.005148:0.011674:0.011716:0.003421:0.011203:0.005798:0.010434:0.011118:0.005148:0.011682:0.011665:0.009168:0.006140:0.005371:0.011203:0.005148:0.006140:0.003421:0.011203:0.011067:0.011682:0.003421:0.003421:0.009168:0.006154:0.011682:0.011716:0.005679
vanced rectal cancer: results of the Ger-:@0.560000:0.427481:0.914551:0.427481:0.914551:0.413475:0.560000:0.413475:0.009476:0.011682:0.010434:0.011067:0.011118:0.011716:0.007629:0.005077:0.011118:0.011067:0.005798:0.011682:0.003421:0.007629:0.011067:0.011682:0.010434:0.011067:0.011118:0.005148:0.004738:0.007629:0.005078:0.011118:0.006636:0.010399:0.003421:0.005798:0.006636:0.007629:0.011203:0.005371:0.007629:0.005798:0.010434:0.011118:0.007629:0.014915:0.011118:0.005148:0.005679
man CAO/ARO/AIO-94 randomized phase :@0.560000:0.441945:0.919301:0.441945:0.919301:0.427939:0.560000:0.427939:0.016044:0.011682:0.010434:0.004943:0.013906:0.012657:0.014864:0.007475:0.012657:0.010382:0.014864:0.007475:0.012657:0.003866:0.014864:0.005679:0.009476:0.009476:0.004943:0.005148:0.011682:0.010434:0.011716:0.011203:0.016044:0.003421:0.007269:0.011118:0.011716:0.004933:0.011665:0.010434:0.011682:0.006636:0.011118:0.004738
III Trial after a median follow-up of 11 years. :@0.560000:0.456408:0.919269:0.456408:0.919269:0.442403:0.560000:0.442403:0.003866:0.003866:0.003866:0.004584:0.006772:0.005148:0.003421:0.011682:0.003421:0.004584:0.011682:0.005371:0.005798:0.011118:0.005148:0.004584:0.011682:0.004584:0.016044:0.011118:0.011716:0.003421:0.011682:0.010434:0.004584:0.005371:0.011203:0.003421:0.003421:0.011203:0.014214:0.005679:0.010399:0.011665:0.004584:0.011203:0.005371:0.004584:0.009476:0.009476:0.004594:0.009168:0.011118:0.011682:0.005148:0.006636:0.004738:0.004738
J Clin Oncol:@0.560000:0.470872:0.659890:0.470872:0.659890:0.456867:0.560000:0.456867:0.008244:0.004738:0.013906:0.003421:0.003421:0.010434:0.004738:0.014864:0.010434:0.011067:0.011203:0.003421
. 2012;30:1926-33.:@0.659890:0.470872:0.802968:0.470872:0.802968:0.456867:0.659890:0.456867:0.004738:0.004738:0.009476:0.009476:0.009476:0.009476:0.004738:0.009476:0.009476:0.004738:0.009476:0.009476:0.009476:0.009476:0.005679:0.009476:0.009476:0.004738
11.   Habr-Gama A,:@0.523653:0.485336:0.682378:0.485336:0.682378:0.471331:0.523653:0.471331:0.009476:0.009476:0.004738:0.004738:0.007919:0.000000:0.011682:0.011682:0.011665:0.005148:0.005679:0.014915:0.011682:0.016044:0.011682:0.004803:0.012657:0.004738
 et al.:@0.682378:0.485336:0.728724:0.485336:0.728724:0.471331:0.682378:0.471331:0.004796:0.011118:0.005798:0.004793:0.011682:0.003421:0.004738
 Operative versus non-:@0.728724:0.485336:0.914556:0.485336:0.914556:0.471331:0.728724:0.471331:0.004796:0.014864:0.011665:0.011118:0.005148:0.011682:0.005798:0.003421:0.009476:0.011118:0.004806:0.009476:0.011118:0.005148:0.006636:0.010399:0.006636:0.004806:0.010434:0.011203:0.010403:0.005679
operative treatment for stage 0 distal rectal :@0.560000:0.499800:0.919303:0.499800:0.919303:0.485795:0.560000:0.485795:0.011203:0.011665:0.011118:0.005148:0.011682:0.005798:0.003421:0.009476:0.011118:0.003712:0.005798:0.005077:0.011118:0.011682:0.005798:0.016044:0.011118:0.010434:0.005798:0.003712:0.005371:0.011203:0.005148:0.003712:0.006636:0.005798:0.011682:0.011511:0.011118:0.003712:0.009476:0.003712:0.011716:0.003421:0.006636:0.005798:0.011682:0.003421:0.003725:0.005078:0.011118:0.011067:0.005798:0.011682:0.003421:0.004738
cancer following chemoradiation therapy: :@0.560000:0.514264:0.919310:0.514264:0.919310:0.500259:0.560000:0.500259:0.011067:0.011682:0.010434:0.011067:0.011118:0.005148:0.005242:0.005371:0.011203:0.003421:0.003421:0.011203:0.014214:0.003421:0.010434:0.011511:0.005251:0.011067:0.010434:0.011118:0.016044:0.011203:0.005148:0.011682:0.011716:0.003421:0.011682:0.005798:0.003421:0.011203:0.010434:0.005241:0.005798:0.010434:0.011118:0.005148:0.011682:0.011665:0.009168:0.004738:0.004738
long-term results. :@0.560000:0.528728:0.704118:0.528728:0.704118:0.514723:0.560000:0.514723:0.003421:0.011203:0.010434:0.011511:0.005679:0.005798:0.011118:0.005612:0.016044:0.004738:0.005075:0.011118:0.006636:0.010399:0.003421:0.005798:0.006636:0.004738:0.004738
Ann Surg.:@0.704118:0.528728:0.782696:0.528728:0.782696:0.514723:0.704118:0.514723:0.012657:0.010434:0.010434:0.004738:0.008518:0.010399:0.005148:0.011511:0.004738
 2004;240:711-7.:@0.782682:0.528728:0.911546:0.528728:0.911546:0.514723:0.782682:0.514723:0.004738:0.009476:0.009476:0.009476:0.009476:0.004738:0.009476:0.009476:0.009476:0.004738:0.009476:0.009476:0.009476:0.005679:0.009476:0.004738
12.   Kopetz S,:@0.523653:0.543192:0.636604:0.543192:0.636604:0.529186:0.523653:0.529186:0.009476:0.009476:0.004738:0.004738:0.007919:0.000000:0.010109:0.011203:0.011665:0.011118:0.005798:0.007269:0.006185:0.008518:0.004738
 et al.:@0.636604:0.543192:0.685753:0.543192:0.685753:0.529186:0.636604:0.529186:0.006199:0.011118:0.005798:0.006193:0.011682:0.003421:0.004738
 Improved survival in meta-:@0.685753:0.543192:0.914560:0.543192:0.914560:0.529186:0.685753:0.529186:0.006197:0.003866:0.016044:0.011665:0.005082:0.011203:0.009476:0.011118:0.011716:0.006197:0.006636:0.010399:0.005148:0.009476:0.003421:0.009476:0.011682:0.003421:0.006209:0.003421:0.010434:0.006199:0.016044:0.011118:0.005798:0.011682:0.005679
static colorectal cancer is associated :@0.560000:0.557656:0.919289:0.557656:0.919289:0.543650:0.560000:0.543650:0.006636:0.005798:0.011682:0.005798:0.003421:0.011067:0.015890:0.011067:0.011203:0.003421:0.011203:0.005075:0.011118:0.011067:0.005798:0.011682:0.003421:0.015890:0.011067:0.011682:0.010434:0.011067:0.011118:0.005148:0.015890:0.003421:0.006636:0.015890:0.011682:0.006636:0.006636:0.011203:0.011067:0.003421:0.011682:0.005798:0.011118:0.011716:0.004738
with  adoption  of  hepatic  resection  and :@0.560000:0.572120:0.919301:0.572120:0.919301:0.558114:0.560000:0.558114:0.014214:0.003421:0.005798:0.010434:0.004738:0.005685:0.011682:0.011716:0.011203:0.011665:0.005798:0.003421:0.011203:0.010434:0.004738:0.005684:0.011203:0.005371:0.004738:0.005682:0.010434:0.011118:0.011665:0.011682:0.005798:0.003421:0.011067:0.004738:0.005685:0.005078:0.011118:0.006636:0.011118:0.011067:0.005798:0.003421:0.011203:0.010434:0.004738:0.005682:0.011682:0.010434:0.011716:0.004738
improved chemotherapy. :@0.560000:0.586583:0.786602:0.586583:0.786602:0.572578:0.560000:0.572578:0.003421:0.016044:0.011665:0.005083:0.011203:0.009476:0.011118:0.011716:0.012520:0.011067:0.010434:0.011118:0.016044:0.011203:0.005798:0.010434:0.011118:0.005148:0.011682:0.011665:0.009168:0.004738:0.004738
J Clin Oncol.:@0.794364:0.586583:0.914556:0.586583:0.914556:0.572578:0.794364:0.572578:0.008244:0.012520:0.013906:0.003421:0.003421:0.010434:0.012520:0.014864:0.010434:0.011067:0.011203:0.003421:0.004738
 :@0.914556:0.586583:0.919294:0.586583:0.919294:0.572578:0.914556:0.572578:0.004738
2009;27:3677-83.:@0.560000:0.601047:0.693602:0.601047:0.693602:0.587042:0.560000:0.587042:0.009476:0.009476:0.009476:0.009476:0.004738:0.009476:0.009476:0.004738:0.009476:0.009476:0.009476:0.009476:0.005679:0.009476:0.009476:0.004738
13.   Holch  JW,:@0.523653:0.615511:0.642175:0.615511:0.642175:0.601506:0.523653:0.601506:0.009479:0.009479:0.004731:0.004738:0.007914:0.000000:0.011511:0.011032:0.003250:0.010895:0.010263:0.004738:0.003243:0.008073:0.014436:0.004738
 et al.:@0.642004:0.615511:0.694052:0.615511:0.694052:0.601506:0.642004:0.601506:0.007988:0.010947:0.005627:0.007988:0.011511:0.003250:0.004738
 The relevance of primary :@0.693881:0.615511:0.919351:0.615511:0.919351:0.601506:0.693881:0.601506:0.007988:0.007115:0.010263:0.010947:0.007988:0.004907:0.010947:0.003250:0.010947:0.009305:0.011511:0.010263:0.010895:0.010947:0.007988:0.011032:0.005200:0.007988:0.011494:0.004977:0.003250:0.015873:0.011511:0.004977:0.009170:0.004738
tumour location in patients with metastatic :@0.560000:0.629975:0.919311:0.629975:0.919311:0.615970:0.560000:0.615970:0.005627:0.010228:0.015873:0.011032:0.010228:0.004977:0.006072:0.003250:0.011032:0.010895:0.011511:0.005627:0.003250:0.011032:0.010263:0.006072:0.003250:0.010263:0.006072:0.011494:0.011511:0.005627:0.003250:0.010947:0.010263:0.005627:0.006465:0.006072:0.014043:0.003250:0.005627:0.010263:0.006072:0.015873:0.010947:0.005627:0.011511:0.006465:0.005627:0.011511:0.005627:0.003250:0.011067:0.004738
colorectal  cancer:  a  meta-analysis  of  first-:@0.560000:0.644439:0.914570:0.644439:0.914570:0.630434:0.560000:0.630434:0.010895:0.011032:0.003250:0.011032:0.004907:0.010947:0.010895:0.005627:0.011511:0.003250:0.004738:0.002730:0.010895:0.011511:0.010263:0.010895:0.010947:0.004977:0.004567:0.004738:0.002728:0.011511:0.004738:0.002730:0.015873:0.010947:0.005627:0.011511:0.005508:0.011511:0.010263:0.011511:0.003250:0.008997:0.006465:0.003250:0.006465:0.004738:0.002730:0.011032:0.005200:0.004738:0.002730:0.004079:0.004079:0.004977:0.006465:0.005627:0.005679
line clinical trials. :@0.560000:0.658903:0.710758:0.658903:0.710758:0.644898:0.560000:0.644898:0.003250:0.003250:0.010263:0.010947:0.011049:0.010895:0.003250:0.003250:0.010263:0.003250:0.010895:0.011511:0.003250:0.011049:0.005627:0.004977:0.003250:0.011511:0.003250:0.006465:0.004567:0.004738
Eur J Cancer.:@0.717070:0.658903:0.838510:0.658903:0.838510:0.644898:0.717070:0.644898:0.008997:0.010228:0.004977:0.011049:0.008073:0.011049:0.013735:0.011511:0.010263:0.010895:0.010947:0.004977:0.004738
 2017;70: :@0.838339:0.658903:0.919294:0.658903:0.919294:0.644898:0.838339:0.644898:0.011049:0.009305:0.009305:0.009305:0.009305:0.004567:0.009305:0.009305:0.004772:0.004738
87-98.:@0.560000:0.673367:0.607465:0.673367:0.607465:0.659361:0.560000:0.659361:0.009305:0.009305:0.005508:0.009305:0.009305:0.004738